Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
暂无分享,去创建一个
J. Dering | R. Finn | D. Slamon | R. Busuttil | C. Ginther | Ronald W. Busuttil | Judy Dering | Charles Ginther | Amrita J. Desai | Dennis J. Slamon | Erika von Euw | Alexey Aleshin | Richard S. Finn | Peter Yang | Amrita Desai | Danyun Zhao | A. Aleshin | Danyun Zhao | E. von Euw | Peter Yang | Erika von Euw
[1] R. Finn,et al. Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC) , 2012 .
[2] D. Amadori,et al. P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer. , 2011 .
[3] N. Ibrahim,et al. Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study , 2011, Clinical Cancer Research.
[4] S. Thorgeirsson,et al. Exploring genomic profiles of hepatocellular carcinoma , 2011, Molecular carcinogenesis.
[5] R. Finn,et al. SRC: a century of science brought to the clinic. , 2010, Neoplasia.
[6] R. Finn. Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now? , 2010, Clinical Cancer Research.
[7] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[8] I. Gelman,et al. Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro , 2009, Digestive Diseases and Sciences.
[9] S. Altekruse,et al. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[11] Derek Y. Chiang,et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.
[12] Jung-Hwan Yoon,et al. Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.
[13] Jin Woo Kim,et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.
[14] Fei Huang,et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.
[15] J. Dering,et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.
[16] S. Boyault,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.
[17] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[18] S. Thorgeirsson,et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.
[19] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[20] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[21] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[22] Timothy J. Yeatman,et al. A renaissance for SRC , 2004, Nature Reviews Cancer.
[23] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[24] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Thorgeirsson,et al. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer , 2002, Hepatology.
[26] M. Monden,et al. Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. , 2001, Journal of hepatology.
[27] H. El‐Serag,et al. Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.
[28] K. Matsumoto,et al. pp60c‐src Activation in hepatocellular carcinoma of humans and LEC rats , 1998, Hepatology.
[29] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.